Sichuan Baili Pharmaceutical Co., Ltd. Drug Pipeline

Sichuan Baili Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 105 trials registered since 2008, of which 102 are currently active. The pipeline spans early- to late-stage development, comprising 50 active Phase 1 trials, 45 Phase 2 trials, and 23 Phase 3 trials. Sichuan Baili’s research is heavily concentrated in Oncology, which accounts for 118 active trials, representing 116% of the active programs. Within Oncology, the leading indications are Advanced Solid Tumor (32 active trials, including 2 in Phase 3), Non-Small Cell Lung Cancer (NSCLC) (17 active trials, including 5 in Phase 3), Breast Cancer (10 active trials, including 1 in Phase 3), Head and Neck Cancer (8 active trials), and Non-Hodgkin Lymphoma (6 active trials). The remaining active trials are in Immunology (2 active trials). The significant number of Phase 3 trials in Oncology, particularly in NSCLC and Solid Tumors, suggests a potential for near-term clinical catalysts.